GlaxoSmithKline announced a $30 billion investment plan over five years enhancing drug production, discovery, and clinical trials in the United States. This move intensifies GSK’s focus on its largest market amid U.K. reimbursement disputes and coincides with heightened biotechnology investments by other pharma companies. Capital projects include a $1.2 billion biologics factory in Pennsylvania and upgrades at multiple sites across states such as North Carolina and Maryland. The commitment underscores a broader pharma trend towards reshoring and increased U.S.-based capacity in response to trade and pricing policy pressures from the current administration.